Market Overview

Bank Of America Sees Significant Manufacturing Capacity Expansions Underway For Pacira Pharmaceuticals

Share:

In a report published Wednesday, Bank of America analyst Steve Byrne reiterated a Buy rating and $105.00 price target on Pacira Pharmaceuticals (NASDAQ: PCRX).

In the report, Bank of America noted, “PCRX CFO Jim Scibetta led a tour yesterday of the company's San Diego-based manufacturing facility, which will soon have $400mn in production sales capacity, post the near-term approval of the second train in Suite C. Debottlenecking and cycle time reductions for both Suite A and C may have effectively added significant upside to this nameplate capacity.. The next tranche of capacity will come from a Suite C-like expansion at Patheon's facility in the UK, which is expected to be on stream in 2H16. A second suite at Patheon is being developed with 2x the capacity of Suite C. PCRX also has a fully functional pilot unit for the new continuous spray process, which is expected to have 3x the throughput of the existing process (e.g. $1bn in revenue capacity for a Suite C size process). Consistent with our prior view, Exparel's long-term revenue potential will not be manufacturing limited.”

Pacira Pharmaceuticals closed on Tuesday at $97.55.

Latest Ratings for PCRX

DateFirmActionFromTo
Nov 2020WedbushMaintainsOutperform
Sep 2020Northland Capital MarketsUpgradesMarket PerformOutperform
Sep 2020NeedhamMaintainsBuy

View More Analyst Ratings for PCRX
View the Latest Analyst Ratings

 

Related Articles (PCRX)

View Comments and Join the Discussion!

Posted-In: Bank of America Steve ByrneAnalyst Color Reiteration Analyst Ratings

Latest Ratings

StockFirmActionPT
HYMCBMO CapitalInitiates Coverage On
DEMorgan StanleyMaintains335.0
SBNYRaymond JamesMaintains138.0
CORTHC Wainwright & Co.Maintains32.0
CYBBFCitigroupDowngrades
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com